OTC Markets OTCPK - Delayed Quote USD

Aptose Biosciences Inc. (APTOF)

1.6500

0.0000

(0.00%)

At close: May 9 at 4:00:00 PM EDT

Aptose Reports First Quarter 2025 Results

Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline TherapySAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2025, and provided a co

GlobeNewswire 3 days ago

APTOF
0.00%
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage pr

GlobeNewswire 6 days ago

APTOF
0.00%
Aptose Announces Auditor Not Standing for Re-Appointment

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointm

GlobeNewswire 18 days ago

APTOF
0.00%
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025. Dr. William G. Rice, Chairman, Pre

GlobeNewswire 18 days ago

APTOF
0.00%

Performance Overview

Return	APTOF	S&P/TSX Composite index (^GSPTSE)
YTD	-77.08%	+2.99%
1-Year	-95.53%	+13.33%
3-Year	-99.67%	+26.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aptose Biosciences Inc. (APTOF)

Aptose Reports First Quarter 2025 Results

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose Announces Auditor Not Standing for Re-Appointment

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Performance Overview